Latest Insider Transactions at Cullinan Oncology, Inc. (CGEM)
This section provides a real-time view of insider transactions for Cullinan Oncology, Inc. (CGEM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cullinan Oncology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cullinan Oncology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 03
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
12,731
-0.16%
|
$369,199
$29.6 P/Share
|
|
Sep 03
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
1,760
-0.69%
|
$51,040
$29.6 P/Share
|
|
Sep 03
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
12,731
-0.16%
|
$369,199
$29.6 P/Share
|
|
Sep 02
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
15,757
-0.2%
|
$456,953
$29.46 P/Share
|
|
Sep 02
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
2,178
-0.84%
|
$63,162
$29.46 P/Share
|
|
Sep 02
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
15,757
-0.2%
|
$456,953
$29.46 P/Share
|
|
Sep 01
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
5,714
-0.07%
|
$165,706
$29.47 P/Share
|
|
Sep 01
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
790
-0.3%
|
$22,910
$29.47 P/Share
|
|
Sep 01
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,714
-0.07%
|
$165,706
$29.47 P/Share
|
|
Aug 31
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
2,838
-0.02%
|
$82,302
$29.79 P/Share
|
|
Aug 31
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
392
-0.08%
|
$11,368
$29.79 P/Share
|
|
Aug 31
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,838
-0.02%
|
$82,302
$29.79 P/Share
|
|
Aug 30
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
31,001
-0.4%
|
$899,029
$29.3 P/Share
|
|
Aug 30
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
4,285
-1.62%
|
$124,265
$29.3 P/Share
|
|
Aug 30
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
31,001
-0.4%
|
$899,029
$29.3 P/Share
|
|
Aug 27
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
13,357
-0.17%
|
$387,353
$29.09 P/Share
|
|
Aug 27
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
1,846
-0.69%
|
$53,534
$29.09 P/Share
|
|
Aug 27
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
13,357
-0.17%
|
$387,353
$29.09 P/Share
|
|
Aug 25
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
1,713
-0.02%
|
$49,677
$29.09 P/Share
|
|
Aug 25
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
237
-0.09%
|
$6,873
$29.09 P/Share
|
|
Aug 25
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,713
-0.02%
|
$49,677
$29.09 P/Share
|
|
Aug 24
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
50,882
-0.65%
|
$1,475,578
$29.48 P/Share
|
|
Aug 24
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
7,025
-2.57%
|
$203,725
$29.48 P/Share
|
|
Aug 24
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
50,822
-0.65%
|
$1,473,838
$29.48 P/Share
|
|
Aug 23
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
53,359
-0.67%
|
$1,547,411
$29.11 P/Share
|
|
Aug 23
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
7,376
-2.63%
|
$213,904
$29.11 P/Share
|
|
Aug 23
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
53,359
-0.67%
|
$1,547,411
$29.11 P/Share
|
|
Aug 23
2021
|
Leigh Zawel Officer |
SELL
Open market or private sale
|
Direct |
28,118
-23.12%
|
$815,422
$29.0 P/Share
|
|
Aug 18
2021
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,000
-7.68%
|
$108,000
$27.79 P/Share
|
|
Aug 18
2021
|
Jennifer Michaelson Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+12.94%
|
$16,000
$4.3 P/Share
|
|
Aug 11
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
2,510
-0.03%
|
$72,790
$29.05 P/Share
|
|
Aug 11
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
347
-0.12%
|
$10,063
$29.05 P/Share
|
|
Aug 11
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,510
-0.03%
|
$72,790
$29.05 P/Share
|
|
Aug 10
2021
|
Patrick Baeuerle Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,000
-100.0%
|
$297,000
$27.0 P/Share
|
|
Aug 10
2021
|
Patrick Baeuerle Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+50.0%
|
$44,000
$4.3 P/Share
|
|
Aug 10
2021
|
Leigh Zawel Officer |
SELL
Open market or private sale
|
Direct |
6,914
-1.82%
|
$186,678
$27.44 P/Share
|
|
Aug 09
2021
|
Leigh Zawel Officer |
SELL
Open market or private sale
|
Direct |
21,204
-7.16%
|
$551,304
$26.82 P/Share
|
|
Jan 12
2021
|
Jeffrey Trigilio Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,250
+50.0%
|
$47,250
$21.0 P/Share
|
|
Jan 12
2021
|
Owen Hughes President and CEO |
BUY
Open market or private purchase
|
Direct |
2,500
+0.49%
|
$52,500
$21.0 P/Share
|
|
Jan 12
2021
|
Morana Jovan Embiricos > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
200,000
+31.64%
|
$4,200,000
$21.0 P/Share
|
|
Jan 12
2021
|
Morana Jovan Embiricos > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
5,826,832
+43.61%
|
-
|
|
Jan 12
2021
|
Ansbert Gadicke Director |
BUY
Open market or private purchase
|
Indirect |
300,000
+3.65%
|
$6,300,000
$21.0 P/Share
|
|
Jan 12
2021
|
Ansbert Gadicke Director |
BUY
Conversion of derivative security
|
Indirect |
7,613,887
+31.4%
|
-
|
|
Jan 12
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
300,000
+3.65%
|
$6,300,000
$21.0 P/Share
|
|
Jan 12
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
7,613,887
+31.4%
|
-
|
|
Jan 07
2021
|
Ansbert Gadicke Director |
BUY
Other acquisition or disposition
|
Direct |
281,268
+50.0%
|
-
|